NO20014780L - Vannlöselige sammensetninger av bioaktive lipofile forbindelser - Google Patents

Vannlöselige sammensetninger av bioaktive lipofile forbindelser

Info

Publication number
NO20014780L
NO20014780L NO20014780A NO20014780A NO20014780L NO 20014780 L NO20014780 L NO 20014780L NO 20014780 A NO20014780 A NO 20014780A NO 20014780 A NO20014780 A NO 20014780A NO 20014780 L NO20014780 L NO 20014780L
Authority
NO
Norway
Prior art keywords
water
lipophilic compounds
bioactive lipophilic
soluble compositions
solubilizing agent
Prior art date
Application number
NO20014780A
Other languages
English (en)
Norwegian (no)
Other versions
NO20014780D0 (no
Inventor
Henryk Borowy-Borowski
Marianna Sikorska-Walker
P Roy Walker
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Publication of NO20014780D0 publication Critical patent/NO20014780D0/no
Publication of NO20014780L publication Critical patent/NO20014780L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
NO20014780A 1999-04-02 2001-10-01 Vannlöselige sammensetninger av bioaktive lipofile forbindelser NO20014780L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/285,244 US6045826A (en) 1999-04-02 1999-04-02 Water-soluble compositions of bioactive lipophilic compounds
PCT/CA2000/000076 WO2000061189A2 (fr) 1999-04-02 2000-02-03 Compositions hydrosolubles de composes lipophiles bioactifs

Publications (2)

Publication Number Publication Date
NO20014780D0 NO20014780D0 (no) 2001-10-01
NO20014780L true NO20014780L (no) 2001-11-27

Family

ID=23093407

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014780A NO20014780L (no) 1999-04-02 2001-10-01 Vannlöselige sammensetninger av bioaktive lipofile forbindelser

Country Status (22)

Country Link
US (2) US6045826A (fr)
EP (2) EP1985308A3 (fr)
JP (1) JP2002541216A (fr)
KR (1) KR20020012167A (fr)
CN (1) CN1352568A (fr)
AT (1) ATE407699T1 (fr)
AU (1) AU775059B2 (fr)
BR (1) BR0009532A (fr)
CA (1) CA2369300C (fr)
CZ (1) CZ20013462A3 (fr)
DE (1) DE60040211D1 (fr)
ES (1) ES2312332T3 (fr)
FI (1) FI20011914L (fr)
HU (1) HUP0200796A2 (fr)
IL (1) IL145703A0 (fr)
MX (1) MXPA01009891A (fr)
NO (1) NO20014780L (fr)
PL (1) PL351548A1 (fr)
RU (1) RU2001129372A (fr)
SK (1) SK13932001A3 (fr)
WO (1) WO2000061189A2 (fr)
ZA (1) ZA200108061B (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034107A1 (en) * 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
US20080070981A1 (en) * 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) * 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US6346544B2 (en) * 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
CA2406570C (fr) * 2000-05-09 2011-07-12 Kaneka Corporation Compositions dermiques ayant la coenzyme q comme principe actif
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
US6403116B1 (en) 2000-11-03 2002-06-11 Triarco Inductries, Inc. Coenzyme Q10 formulation
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6864231B2 (en) * 2001-01-09 2005-03-08 Pharmachem Laboratories, Inc. Glycoprotein matrix compositions and methods related thereto
US6806069B2 (en) 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
DE10106746A1 (de) * 2001-02-14 2002-09-05 Goldwell Gmbh Haarfärbemittel
JP3742602B2 (ja) * 2001-05-09 2006-02-08 株式会社カネカ 還元型補酵素ｑの安定な溶液
US20030044474A1 (en) * 2001-08-03 2003-03-06 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
FR2829762B1 (fr) 2001-09-17 2004-02-13 Fabre Pierre Dermo Cosmetique Bioprecurseurs destines a une application percutanee
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
MXPA04002446A (es) * 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
JP3822479B2 (ja) 2001-10-10 2006-09-20 株式会社カネカ 還元型補酵素ｑ水溶液の安定化組成
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
US6652891B2 (en) 2001-12-12 2003-11-25 Herbasway Laboratories, Llc Co-enzyme Q10 dietary supplement
TW200302055A (en) * 2002-01-18 2003-08-01 Kaneka Corp Ubiquinol-enriched fat-containing foods
US6683194B2 (en) 2002-02-05 2004-01-27 Sonus Pharmaceuticals, Inc. Tocopherol derivatives
US20040034093A1 (en) * 2002-05-30 2004-02-19 Hensley Kenneth L. Methods for enhancing motor performance and/or endurance
US7306819B2 (en) * 2002-06-12 2007-12-11 The Coca-Cola Company Beverages containing plant sterols
DK1549159T3 (da) * 2002-06-12 2009-03-02 Coca Cola Co Drikkevarer indeholdende plantesteroler
AU2003240300A1 (en) * 2002-06-25 2004-01-06 Cosmeceutic Solutions Pty Ltd Topical cosmetic compositions
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
EP1591020A4 (fr) * 2003-01-17 2006-04-26 Taiyo Kagaku Kk Compositions contenant une coenzyme q10
US7258876B2 (en) * 2003-02-05 2007-08-21 Craig Bozzacco Topical composition for treating infectious conditions of skin and mucosa
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
ITMI20031767A1 (it) * 2003-09-16 2005-03-17 Visufarma S R L Coenzima q10 come agente antiapoptotiico e sue applicazioni.
US20050074445A1 (en) * 2003-10-01 2005-04-07 Papas Andreas M. Alpha-tocopherol treatment for cystic fibrosis
US20050163828A1 (en) * 2003-10-27 2005-07-28 Bernard Bobby L. Tocopheryl polyethylene glycol succinate articles and process for preparing TPGS articles
US20080045559A1 (en) * 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
CA2543722C (fr) * 2003-10-29 2011-01-04 Sonus Pharmaceuticals, Inc. Composes medicamenteux a base de tocopherol modifie
JP2007520555A (ja) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド 自己安定化剤の使用により調製された分散剤
US20060069157A1 (en) * 2004-02-19 2006-03-30 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, by sodium butyrate chemotherapy
US7790190B2 (en) * 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
NZ550856A (en) * 2004-05-06 2010-11-26 Samyang Corp Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylactic acid derivative
US7803366B2 (en) * 2004-05-07 2010-09-28 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20060165769A1 (en) * 2004-09-30 2006-07-27 Hyatt John A Pharmaceutical formulations containing vitamin E TPGS molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
CN101031284A (zh) * 2004-09-30 2007-09-05 伊斯曼化学公司 使亲脂性药物增溶而无显著外排抑制作用的含有维生素e tpgs分子的药物制剂和该制剂的用途
US7901675B2 (en) * 2004-10-13 2011-03-08 U.S. Department Of Veterans Affairs Method of using coenzyme Q10 to treat Huntington's disease
US20060088558A1 (en) * 2004-10-26 2006-04-27 Robert Jandzinski Vitamin E TPGS fluid concentrate comprising a low percentage of water
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US8067217B2 (en) * 2004-12-28 2011-11-29 Kaneka Corporation Method for preserving reduced coenzyme Q10
WO2006092449A2 (fr) * 2005-03-02 2006-09-08 Metanomics Gmbh Procede de production de produits chimiques fins
JP2008534619A (ja) * 2005-04-01 2008-08-28 ザイムス， エルエルシー ＣｏＱ１０を送達システムとして使用する皮膚強化
US20060257385A1 (en) * 2005-04-14 2006-11-16 Rogovin Jarrow L Dietary supplement formulations for improved delivery of coenzyme Q10 and methods of administration
AU2006235633A1 (en) * 2005-04-14 2006-10-19 Jarrow Formulas, Inc. Dietary supplement formulations for improved delivery of coenzyme Q10 and methods of administration
EA035619B1 (ru) 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
US8252326B2 (en) * 2005-06-01 2012-08-28 Catalent Australia Pty Ltd. Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10
JP2008543842A (ja) * 2005-06-14 2008-12-04 バクスター インターナショナル インコーポレイテッド 薬物−薬物相互作用を最小にするための薬学的処方物
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
JP2009508867A (ja) * 2005-09-15 2009-03-05 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体
AU2006315177A1 (en) * 2005-11-15 2007-05-24 Baxter Healthcare S.A. Compositions of lipoxygenase inhibitors
EP1986636B1 (fr) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Derives du phenol et de la 1,4-benzoquinone pour leur utilisation dans le traitement des maladies mitochondriales
US20090246186A1 (en) 2006-03-29 2009-10-01 Kaneka Corporation Agent for improving nervous system cell functions
EP2011498A4 (fr) * 2006-04-10 2009-11-11 Mitsubishi Gas Chemical Co Agent ameliorant les fonctions cerebrales et aliment fonctionnel contenant l'agent ameliorant
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
JP2008156326A (ja) * 2006-12-26 2008-07-10 Shiseido Co Ltd 化粧料
CA2677253C (fr) * 2007-02-01 2015-06-30 National Research Council Of Canada Formulations de molecules bioactives lipophiles
WO2008101344A1 (fr) * 2007-02-22 2008-08-28 Peter Tomlinson Compositions de composés lipophiles bioactifs solubles
WO2008116021A1 (fr) * 2007-03-19 2008-09-25 Zymes, Llc Composés organoleptiques présentant des propriétés améliorées
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
MX2010010050A (es) * 2008-03-20 2011-03-15 Virun Inc Star Emulsiones que incluyen un derivado de polietilen glicol de tocoferol.
BRPI0909185A2 (pt) 2008-03-20 2015-08-25 Virun Inc Derivado de vitamina e e seus usos
US8337931B2 (en) * 2008-06-23 2012-12-25 Virun, Inc. Compositions containing non-polar compounds
US20100041622A1 (en) * 2008-08-13 2010-02-18 Bromley Philip J Compositions containing aminoalkanes and aminoalkane derivatives
EP2344142B1 (fr) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Traitement de troubles globaux du développement grâce à des agents thérapeutiques à activité oxydo-réductrice
CN102413813B (zh) * 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
KR20100118418A (ko) * 2009-04-28 2010-11-05 (주)유진사이언스 콜레스테롤 저하효과를 갖는 수용성 스테롤 유도체 및 그의 제조방법
WO2011060084A1 (fr) * 2009-11-10 2011-05-19 MyCell Holdings Limited Formulations stabilisées d'acides gras
US9656985B2 (en) * 2009-12-01 2017-05-23 Mycell Technologies, Llc Surfactant-enabled transition metal-catalyzed chemistry
AU2010326026B2 (en) * 2009-12-01 2016-11-17 Mycell Technologies, Llc Surfactant-enabled transition metal-catalyzed chemistry
US8785665B2 (en) * 2009-12-01 2014-07-22 Mycell Technologies, Llc Surfactant-enabled transition metal-catalyzed chemistry
BR112012023052A2 (pt) * 2010-03-12 2019-09-24 Kip Biotech Llc derivados de fitosterol solúveis em água para reduzir colesterol e preparação dos mesmos
EP2563164B1 (fr) * 2010-03-23 2016-06-29 Virun, Inc. Nanoemulsions comprenant des ester d'acide gras de sucrose
WO2011162802A1 (fr) 2010-06-21 2011-12-29 Virun, Inc. Compositions contenant des composés non polaires
US20140239525A1 (en) * 2011-06-17 2014-08-28 Board Of Regents, University Of Texas System Inhalable pharmaceutical compositions
CA2863544C (fr) 2012-02-10 2019-03-26 Virun, Inc. Compositions de boisson contenant des composes non polaires
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
HK1220872A1 (zh) 2013-03-15 2017-05-19 Virun, Inc. 维生素e水溶性衍生物制剂及包含其的组合物
US9040034B2 (en) 2013-04-09 2015-05-26 International Business Machines Corporation Vitamin functionalized gel-forming block copolymers for biomedical applications
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
JP2017505778A (ja) * 2014-01-29 2017-02-23 ヒューメディックス カンパニー，リミテッド ペグ化７−デヒドロコレステロール誘導体
WO2016044813A1 (fr) 2014-09-18 2016-03-24 Virun, Inc. Pré-émulsions de pulvérisation et poudres contenant des composés non polaires
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
EP3389646A1 (fr) 2015-12-17 2018-10-24 BioElectron Technology Corporation Dérivés fluoroalkyle, fluoroalcoxy, phénoxy, hétéroaryloxy, alcoxy, et amine 1,4-benzoquinone pour le traitement de troubles du stress oxydatif
CN106565948A (zh) * 2016-10-12 2017-04-19 武汉桀升生物科技有限公司 一种植物甾醇聚乙二醇琥珀酸酯的制备方法
JP2020522399A (ja) 2017-05-15 2020-07-30 ナショナル リサーチ カウンシル オブ カナダ 伸縮性ナノコンポジットスキン材料および関連構造体
IT201700120582A1 (it) * 2017-10-24 2019-04-24 Difass Int S R L Composizione comprendente coenzima q10 e piperina da estratti vegetali
PT3476388T (pt) 2017-10-24 2021-12-15 Difass Int S R L Composição que compreende coenzima q10 e piperina
US20200138772A1 (en) 2018-07-09 2020-05-07 Volker Berl Stabilized formulations of cannabinoid compositions
CN113527530B (zh) * 2021-08-06 2022-04-29 青岛职业技术学院 一种水溶性虾青素岩藻多糖酯的制备方法
CN115281154B (zh) * 2022-08-30 2023-11-03 中国人民解放军联勤保障部队第九〇四医院 一种伪无菌大鼠模型的构建方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2680749A (en) * 1951-12-01 1954-06-08 Eastman Kodak Co Water-soluble tocopherol derivatives
US3004043A (en) * 1959-10-09 1961-10-10 Eastman Kodak Co Water-soluble vegetable oil sterol derivatives
US3102078A (en) * 1961-01-13 1963-08-27 Eastman Kodak Co Water-dispersible vitamin preparations
JPS53100175A (en) * 1977-02-14 1978-09-01 Sumitomo Chem Co Ltd Microencapsulating method for hydrophobic liquid
US4189400A (en) * 1977-08-17 1980-02-19 Bonderman Dean P Compound useful in cholesterol assay procedures
US4224229A (en) * 1977-08-17 1980-09-23 Proksch Gary J Compound useful in cholesterol assay procedures
JPS55104358A (en) * 1979-02-07 1980-08-09 Mitsui Toatsu Chem Inc Production of liquid preparation of water-insoluble azo dye
DE3440488A1 (de) * 1984-11-06 1986-05-07 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung hochkonzentrierter waessriger presskuchen von feststoffen
JPS61155426A (ja) * 1984-12-28 1986-07-15 Res Dev Corp Of Japan 抗血栓性を有する医療用材
DE3829641A1 (de) * 1988-09-01 1990-03-15 Roecar Holdings Nv Transdermal anwendbare pharmazeutische zubereitungen mit sterolinen und/oder spiroketalinen
JPH0429924A (ja) * 1990-05-28 1992-01-31 Terumo Corp 脂溶性薬物含有注射用製剤
CA2044663A1 (fr) * 1990-07-12 1992-01-13 Makoto Tanaka Complexes antifongiques a base de polyene hydrodispersable
US5234695A (en) * 1990-07-24 1993-08-10 Eastman Kodak Company Water dispersible vitamin E composition
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
DE4107283A1 (de) * 1991-03-07 1992-09-10 Henkel Kgaa Spinnpraeparationen fuer synthetische filamentfasern
DE4109473A1 (de) * 1991-03-22 1992-09-24 Kleeberg Hubertus Dr Verfahren zur herstellung eines lagerfaehigen azadirachtinreichen insektizids aus samenkernen des neem-baumes
WO1993000890A1 (fr) * 1991-07-09 1993-01-21 Vitaphore Corporation Compose de liberation controlee d'un medicament a base de collagene
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
DE4327135A1 (de) * 1993-08-12 1995-02-16 Trw Repa Gmbh Gurtaufroller für Sicherheitsgurt-Rückhaltesysteme in Fahrzeugen
WO1995012385A1 (fr) * 1993-11-03 1995-05-11 Isotech Medical, Inc. Compositions pharmaceutiques microparticulaires sous forme micellaire
AU684950B2 (en) * 1994-05-06 1998-01-08 Alcon Laboratories, Inc. Use of vitamin E tocopheryl derivatives in ophthalmic compositions
WO1995033490A1 (fr) * 1994-06-02 1995-12-14 Enzon, Inc. Procede de solubilisation de substances pratiquement insolubles dans l'eau
JPH0839077A (ja) * 1994-07-27 1996-02-13 Nippon Parkerizing Co Ltd 非イオン性界面活性剤含有排液の処理方法
HU215966B (hu) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
CA2207093A1 (fr) * 1994-12-06 1996-06-13 National Research Council Of Canada Compositions a base d'ubiquinones solubles dans l'eau, precurseurs de medicaments, ainsi que les procedes y ayant trait
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
US5593682A (en) * 1995-12-29 1997-01-14 Eastman Chemical Company Skin treating composition
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
JP2001523221A (ja) * 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
US5798333A (en) * 1996-09-17 1998-08-25 Sherman; Bernard C. Water-soluble concentrates containing cyclosporins
US5770528A (en) * 1996-12-31 1998-06-23 Kimberly-Clark Worldwide, Inc. Methylated hydroxypropylcellulose and temperature responsive products made therefrom
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
AU2946600A (en) * 1999-03-04 2000-09-21 Eugene Science Inc. Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same

Also Published As

Publication number Publication date
PL351548A1 (en) 2003-05-05
CZ20013462A3 (cs) 2002-06-12
WO2000061189A3 (fr) 2001-01-11
AU775059B2 (en) 2004-07-15
CA2369300C (fr) 2010-06-08
WO2000061189A2 (fr) 2000-10-19
FI20011914A7 (fi) 2001-11-19
US6191172B1 (en) 2001-02-20
ES2312332T3 (es) 2009-03-01
AU2273400A (en) 2000-11-14
HUP0200796A2 (en) 2002-08-28
US6045826A (en) 2000-04-04
MXPA01009891A (es) 2003-07-21
DE60040211D1 (de) 2008-10-23
IL145703A0 (en) 2002-07-25
CN1352568A (zh) 2002-06-05
EP1159006A2 (fr) 2001-12-05
SK13932001A3 (sk) 2002-05-09
EP1985308A2 (fr) 2008-10-29
ATE407699T1 (de) 2008-09-15
FI20011914L (fi) 2001-11-19
RU2001129372A (ru) 2004-02-20
BR0009532A (pt) 2001-12-26
KR20020012167A (ko) 2002-02-15
CA2369300A1 (fr) 2000-10-19
JP2002541216A (ja) 2002-12-03
EP1985308A3 (fr) 2011-11-16
ZA200108061B (en) 2003-01-02
EP1159006B1 (fr) 2008-09-10
NO20014780D0 (no) 2001-10-01

Similar Documents

Publication Publication Date Title
NO20014780D0 (no) Vannlöselige sammensetninger av bioaktive lipofile forbindelser
DE69627253T2 (de) Fenofibrathaltige neue galenische Arzneizusammensetzungen und ihre Verwendung
EP1810694A3 (fr) Compositions hydrosolubles de composes lipophiles bioactifs
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
CA2289202A1 (fr) Formulations pharmaceutiques solides contenant un melange physique de sulfoalkyl ether cyclodextrine et un agent therapeutique
AU3455699A (en) Water soluble paclitaxel derivatives
WO2001066085A3 (fr) Compositions pharmaceutiques destinees a une application buccale et pulmonaire
CA2206532A1 (fr) Nouveau derive d'amidinonaphtyle ou sel de celui-ci
HUP0203509A3 (en) Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
HK1056181A1 (zh) 作為抗炎劑的17β-硫代羧酸酯17α-芳基羰氧基氧雄甾烷衍生物
ATE442147T1 (de) Pharmazeutische zubereitung enthaltend drospirenon
MXPA01007609A (es) Gcsf conjugados.
CA2303498A1 (fr) Acides dioxocyclopentylhydroxamiques
CA2410065A1 (fr) Compositions micellaires pharmaceutiques pour applications buccale et pulmonaire
WO1999051271A3 (fr) Formulations de cosolvants
GB2334446A (en) Aqueous compositions compromising a lipid and a lanolin-derived surfactant,and their use
CA2367387A1 (fr) Composition comprenant de l'isoquercetine et de l'acide ascorbique a liberation prolongee
WO2004000045A3 (fr) Compositions liquides contenant des oligosaccharides non-digestibles et des catechines de the vert, leurs procede et utilisations
ES2174591T3 (es) Composiciones cosmeticas para las axilas con acetato de alquilo inferior.
DE69918104D1 (de) Oral anwendbare zubereitungen enthaltend ein kationvernetztes polysaccharid und ein im unteren intestinalen bereich abbaubares polymer
CY2007011I1 (el) Πολυμορφες ενος κρυσταλλικου κιτρικου αλατος αζαδικυκλο (2,2,2) οκταν -3- αμινης και φαρμακευτικες συνθεσεις τους
WO1994012143A3 (fr) Utilisation de furanones a titre d'ingredients parfumants
WO2000054763A3 (fr) Composition de dhea et procede
CA2406629A1 (fr) Utilisation de derives d'acide biliaires associes a des complexes chelates d'ions metalliques aux fins du diagnostic de la permeabilite microvasculaire
AU2001278804A1 (en) 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients